Over 300 Texas Auctions End Today - Bid Now
Over 30 Total Lots Up For Auction at Two Locations - WI 05/27, NV 05/29

Adel Abdullah and Aaron Hargrave

Positron appoints president and vice president
October 12, 2018
Molecular Imaging PET
NIAGARA FALLS, N.Y., Sept. 27, 2018 /PRNewswire/ -- Positron Corporation (OTC :POSC )(the "Company"), a nuclear medicine healthcare company, announces the appointment of Adel Abdullah as its President. Mr. Abdullah will also serve as a Director of the Board. Mr. Abdullah will lead the Company in its strategic plan and long term objectives moving forward. Adel Abdullah has been instrumental to Positron's ability to deliver world class PET imaging technology, clinical & technical services to customers for over 10 years and will continue to do so for Positron's customers.

Positron is also pleased to announce the appointment of Aaron Hargrave, Positron's Director of Clinical Applications as Vice President. Mr. Hargrave is a Certified Nuclear Medicine Technologist, performing PET imaging in cardiac, oncology and neurologic subsets for Positron since 2010. Mr. Hargrave provides clinical and software support and training for Positron's Attrius PET customers specializing in image quality and interpreting technical data, ensuring proper product use for optimal patient outcomes.

Mr. Abdullah and Mr. Hargrave have delivered top performing PET technology used in over 50,000 cardiac studies on Positron imaging systems.
stats Advertisement
DOTmed text ad

Training and education based on your needs

Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money

stats
Mr. Abdullah stated, "It is an exciting time at Positron. As a company we are on a new path that I expect will have great impact in the growth of the cardiac PET industry. Positron is stronger than ever with the ability to focus exclusively on its imaging technology, clinical services and innovative pro-business structures for its customers. Our goal is to work with champions of the cardiac PET industry to advance the adoption of cardiac PET utilizing Positron's PET imaging systems and services."


About Positron:
Positron Corporation is a nuclear medicine healthcare company providing innovative PET technologies and practice solutions that are reshaping the field of nuclear cardiology. Through proprietary PET imaging systems, services and solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes, while practicing cost effective medicine. Positron has made continues their strong commitment to excellence and advancing cardiac imaging solutions. Positron's unique products, market position and approach in facilitating the adoption of cardiac PET to customers are substantial advantages to the growth of nuclear cardiology and Positron. Positron is redefining the industry.


SOURCE Positron Corporation

You Must Be Logged In To Post A Comment

 

advertisement

Molecular Imaging Homepage

EXPLORER scanner cuts total-body PET imaging time for cancer detection to 20 minutes
Uses a variation of the Patlak plot — called the relative Patlak plot — to generate high-quality parametric images
OEMs dominate PET/CT service landscape, IMV reports
Among midsized hospitals, OEM support stood at 77%, with 20% in-house and 13% ISO
IBA debuts compact synthesizer for radiopharmaceutical manufacturing
CASSY is designed to integrate into existing lab workflows and optimize space within hot cells
Ratio Therapeutics plans radiopharmaceutical manufacturing site in Salt Lake City
Designed for end-to-end production of radiopharmaceuticals, with an eye toward scaling up for commercial supply
SHINE Technologies to acquire Lantheus’ SPECT division
Deal includes the manufacturing operations at Lantheus’ North Billerica, Massachusetts site
Blue Earth Therapeutics begins phase 2 trial of lutetium-based radioligand for prostate cancer
Assessing efficacy and safety across different dosing regimens
SpectronRx passes FDA inspection with no observations for Indianapolis facility
Plans to expand operations to meet global demand for radiopharmaceuticals
SHINE enters UAE market with Modawina partnership for Lu-177 distribution
Extends presence across the Europe, Middle East, and Africa regions
PET procedure volumes in US rose 12% in 2024
Demand grew alongside limited expansion in installed imaging capacity, according to IMV
SHINE and Sumitomo form partnership to expand radioisotope supply in Asia
The agreement will focus on establishing supply chains for SHINE’s core offerings